
    
      This was a Canadian post-marketing observational study (PMOS) utilizing a prospective cohort
      design. Participants were entered into one of two study cohorts (adalimumab cohort or
      topical/traditional systemic cohort) at the time of change of their psoriasis treatment for
      any reason and were followed for a maximum of 24 months with recommended assessments at 3, 6,
      12, 18 and 24 months after baseline. Treatment of the participants and follow up were
      according to the physician's judgment, regional regulations, and the product monograph.
      Off-label use was not permitted, and these participants were not included in the study. Dose
      changes including escalation were allowed as per the physician's judgment for participants
      that were treated as per indication when they were enrolled in the study.
    
  